What is KLOW peptide?

KLOW is a four-peptide research formulation, sold variously as the KLOW blend, KLOW 80mg or — as we list it — the Klow Stack. The name is an industry convention rather than a brand: wherever you see it, it refers to the same four compounds in one vial, GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg) and TB-500 (10mg), 80mg total. Presenting four peptides with distinct mechanisms in one vial lets researchers investigate combined activity across multiple signalling pathways simultaneously, under standardised conditions.

Research use only. The Klow Stack is supplied strictly for in-vitro laboratory research. This page does not describe dosing, administration, or use in humans or animals, and makes no therapeutic claims.

What is in KLOW

The name is most readily understood as KPV added to GLOW — the three-compound Glow Stack with the α-MSH fragment included — which is also exactly what the composition is. It is a usage convention rather than a formal or trademarked name, so what matters is the composition rather than the label.

• GHK-Cu — 50mg. A copper-peptide complex: the tripeptide glycyl-L-histidyl-L-lysine bound to a divalent copper ion. It is the bulk of the vial by mass, and it is studied as a carrier that holds copper in a bound form, allowing copper-dependent signalling to be examined without introducing a free metal salt. See the GHK-Cu guide for the detail.
• KPV — 10mg. The C-terminal 11-13 tripeptide fragment of α-MSH (Lys-Pro-Val), investigated in melanocortin-linked and inflammatory signalling research. Small, and studied at correspondingly small quantities. See the KPV guide.
• BPC-157 — 10mg. A synthetic pentadecapeptide sequence used widely as a probe for peptide-mediated signalling mechanisms in cultured systems.
• TB-500 — 10mg. A 17-amino-acid synthetic fragment of thymosin beta-4, examined in actin-binding and cytoskeletal-dynamics research.

80mg total in one vial. Note that the mass is not evenly split: GHK-Cu accounts for roughly five-eighths of the material, and the remaining three compounds share the rest equally. That distribution matters when interpreting any result from the combined preparation, and it is the first thing to check when comparing one supplier's KLOW against another's — the name does not guarantee the ratio.

Why the four are combined

The research rationale for a multi-compound vial is that the four have distinct and largely non-overlapping mechanisms: copper-dependent signalling, melanocortin-linked signalling, a general peptide-signalling probe, and cytoskeletal dynamics. Presenting them together in one preparation supports two kinds of question that separate vials make harder to ask.

The first is convergent and parallel signalling — whether pathways that are usually studied in isolation interact when stimulated in the same system, and whether the combined response differs from the sum of the individual ones.

The second is simply experimental control. Four separate preparations mean four reconstitutions, four sets of pipetting error and four opportunities for concentration drift. A single characterised vial removes that variance, which is the practical reason blends appear in comparative protocols at all.

It is worth being clear about the limitation, too: a combined preparation cannot tell you which component produced an observed effect. Blends are useful for asking whether something happens; single compounds are needed to ask why. Serious protocols usually run both, which is why we supply the components individually as well.

KLOW and the Glow Stack

The two sets are frequently confused because they share three of four components.

• Glow Stack — GHK-Cu, BPC-157 and TB-500. Three compounds.
• Klow Stack — the same three, plus KPV. Four compounds.

KLOW is Glow with the α-MSH fragment added. If the melanocortin-linked arm is not part of your question, the three-compound set is the simpler preparation and the cleaner control. The Glow Stack guide covers that composition.

What the research on the components actually examines

Searches for KLOW frequently return benefit lists. It is worth separating what the primary literature examines from what gets claimed downstream, because the distance between the two is substantial.

The published work on these compounds is in-vitro and preclinical: cultured fibroblasts, keratinocyte lines, dermal papilla cells, and animal models. Findings concern gene expression, cell behaviour and biochemical pathways under defined culture conditions. Outcomes vary considerably with concentration, exposure time and model system, and results in one system are not evidence for another.

Critically, there is very little published research on the four-compound combination itself. The literature covers the components individually. Claims about what "KLOW does" are therefore extrapolations from separate single-compound studies, not findings about the blend — and extrapolating from four individual in-vitro results to a combined effect in a living system is not a step the evidence supports.

None of this makes the preparation uninteresting as a research tool. It means the research question and the marketing claim are different things, and we would rather say so.

Reading the certificate for a blend

Blends are harder to verify than single compounds, and the documentation is where the difference shows.

A single-compound COA reports one purity figure for one molecule. A four-component blend should account for each component — identity and the quantity present — rather than reporting a single number for the vial. A certificate that states "99% pure" for an 80mg four-peptide preparation without breaking down what is in it has not told you the thing you needed to know.

Points worth checking on any blend certificate:

• Per-component identity, not just a combined mass
• The stated ratio, so you can confirm the 50/10/10/10 split rather than assume it
• A batch reference that matches the vial in front of you
• The analytical method — HPLC for purity, mass spectrometry for identity
• A date, since peptide material is not indefinitely stable

Recent certificates sit in our COA library so the format can be reviewed before ordering.

Why format matters more for a blend

Reconstitution introduces variability at the best of times. With a four-component preparation it introduces it four times over, and unevenly — the components do not necessarily go into solution at the same rate, so an incompletely mixed vial does not deliver the stated ratio.

Our Klow Stack ships as a pre-mixed solution prepared under controlled conditions, which removes that step entirely. For a blend this matters more than it does for a single compound: the ratio is the product, and a ratio that depends on how thoroughly the end user mixed a powder is not a controlled variable.

Store refrigerated at 2–8°C. If you need to work out concentrations from the vial, the peptide calculator handles the arithmetic.

What KLOW is not

• It is not an approved medicine in the UK or anywhere else, and is not supplied for human or veterinary use.
• It is not a branded formulation — the name is an industry convention, so two suppliers' KLOW can differ in ratio even at the same total mass.
• It is not a substitute for single-compound work, for the attribution reason above.

Dosing and administration

We do not publish dosing, reconstitution-for-use or administration guidance for the Klow Stack. The material is supplied strictly for in-vitro laboratory research and is not for human or veterinary use, so quantity guidance aimed at a person would be inconsistent with what is actually supplied. Experimental concentrations are specific to the model and endpoint and belong in the primary literature.

How it is supplied

The Klow Stack is supplied as a pre-mixed 80mg vial — GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, TB-500 10mg — with a batch-specific Certificate of Analysis, dispatched from our UK facility under cold-chain handling and stored refrigerated at 2–8°C.

The components are also available individually: GHK-Cu, KPV, BPC-157 and TB-500.

Related reading

• What is GHK-Cu? · What is KPV? · What is the Glow Stack?